>latest-news

Noul Signs Supply Agreement For AI Blood Testing In Indonesia

Noul partners with PT Kirana to distribute AI-driven blood analysis in Indonesia.

Breaking News

  • Oct 15, 2024

  • Simantini Singh Deo

Noul Signs Supply Agreement For AI Blood Testing In Indonesia

Noul, a South Korean firm focused on AI-based diagnostics for blood and cancer, announced on Monday a three-year partnership with Indonesian medical device distributor PT Kirana Jaya Lestari. This agreement will enable the distribution of Noul's AI-driven blood analysis solution, miLab BCM, to hospitals and screening facilities throughout Indonesia.


The miLab BCM streamlines the blood testing process by accurately identifying morphologically abnormal blood cells and generating digital images for each specimen. Its compact design facilitates easy setup and maintenance, making it adaptable for laboratories of various sizes. Noul highlighted that the system not only lowers the costs associated with establishing a digital pathology framework but also minimises the need for highly skilled labour. Furthermore, results can be accessed remotely, reflecting the increasing shift toward digital healthcare solutions globally.


Indonesia's telemedicine sector is experiencing significant growth, largely due to its unique status as an archipelago. The government's initiative to transform the healthcare system aims to enhance the absolute neutrophil count, which is anticipated to greatly increase the volume of blood tests evaluating white blood cells, red blood cells, and platelets.


In addition to this, Noul has achieved global acclaim for its cancer diagnostics technology. A recent report by Unitaid, an international health organisation dedicated to promoting innovative solutions for major diseases in low- and middle-income nations, has endorsed Noul's AI-driven cervical cancer diagnostic tool, miLab CER, for use in screening tests. This endorsement places it among just three other notable products, including Roche's CINtec Plus Cytology, which employs dual staining technology, and Hologic's ThinPrep Imaging System and Genius Digital Diagnostics System, both designed for computer-assisted cytology.


Lim Chan-yang, CEO of Noul, said that “Noul's miLab BCM is an innovative product that could replace peripheral blood smears (PBS) , a procedure performed over 680 million times worldwide. The product caters to both large and small diagnostic laboratories, and we are currently seeking U.S. Food and Drug Administration (FDA) clearance due to rising demand in Asia and developed countries.”

Ad
Advertisement